Eurobio Scientific SA
PAR:ALERS

Watchlist Manager
Eurobio Scientific SA Logo
Eurobio Scientific SA
PAR:ALERS
Watchlist
Price: 25.345 EUR 0.18% Market Closed
Market Cap: 259.8m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ALERS stock under the Base Case scenario is 33.083 EUR. Compared to the current market price of 25.345 EUR, Eurobio Scientific SA is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALERS Relative Value
Base Case
33.083 EUR
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.8
P/S
P/S
Price to Sales
1.8
vs History
14
vs Industry
80
Median 3Y
1.3
Median 5Y
1.3
Industry
6.9
Forward
1.8
More Details
38.3
P/E
P/E
Price to Earnings
38.3
vs History
11
vs Industry
4
Median 3Y
20.5
Median 5Y
7.4
Industry
22.4
Forward
27.4
More Details
11
P/OCF
P/OCF
Price to OCF
11
vs History
22
vs Industry
13
Median 3Y
5.4
Median 5Y
5.2
Industry
19.1
More Details
104.7
P/FCFE
P/FCFE
Price to FCFE
104.7
vs History
7
vs Industry
2
Median 3Y
5
Median 5Y
4.1
Industry
23.2
More Details
1.4
P/B
P/B
Price to Book Value
1.4
vs History
49
vs Industry
51
Median 3Y
1.2
Median 5Y
1.4
Industry
2.5
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
15
vs Industry
69
Median 3Y
1.3
Median 5Y
1.3
Industry
7.5
Forward
1.7
More Details
3.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.7
vs History
17
vs Industry
63
Median 3Y
2.9
Median 5Y
2.7
Industry
8.9
More Details
8.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.5
vs History
12
vs Industry
12
Median 3Y
5.7
Median 5Y
5.3
Industry
4
Forward
8.8
More Details
17.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17.5
vs History
12
vs Industry
8
Median 3Y
10.2
Median 5Y
7.9
Industry
3.7
Forward
10.3
More Details
10.7
EV/OCF
EV/OCF
Enterprise Value to OCF
10.7
vs History
22
vs Industry
13
Median 3Y
5.8
Median 5Y
5.7
Industry
4.5
More Details
12.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.3
vs History
22
vs Industry
9
Median 3Y
7
Median 5Y
6.3
Industry
3.4
More Details
1.1
EV/IC
EV/IC
Enterprise Value to IC
1.1
vs History
53
vs Industry
55
Median 3Y
0.9
Median 5Y
1.2
Industry
4.6
More Details

Multiples Across Competitors

ALERS Competitors Multiples
Eurobio Scientific SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Eurobio Scientific SA
PAR:ALERS
254.1m EUR 1.8 38.3 8.5 17.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 071 678.8 -166 690.5 -202 415.4 -200 105.6
US
Abbvie Inc
NYSE:ABBV
330.4B USD 5.9 78 15.5 23.3
US
Amgen Inc
NASDAQ:AMGN
145.2B USD 4.3 35.5 14.8 26.1
US
Gilead Sciences Inc
NASDAQ:GILD
122B USD 4.2 254.1 10.1 12.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD 10.5 -215.9 23.5 24.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 008.7 -512.6 -558.2 -543.3
AU
CSL Ltd
ASX:CSL
118.9B AUD 5.1 28.2 17.4 21.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.2B USD 4.3 13.9 8.4 9.4
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.3 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
34.6B EUR 17.9 46.9 -2 653.2 -1 778.9
P/S Multiple
Revenue Growth P/S to Growth
FR
Eurobio Scientific SA
PAR:ALERS
Average P/S: 3 188 523.7
1.8
9%
0.2
FR
Pharnext SCA
OTC:PNEXF
35 071 678.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.3
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.2
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1
US
E
Epizyme Inc
F:EPE
2 008.7
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
6%
0.7
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
39%
0.5
P/E Multiple
Earnings Growth PEG
FR
Eurobio Scientific SA
PAR:ALERS
Average P/E: 70.7
38.3
52%
0.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 690.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
35.5
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
254.1
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -215.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.6 N/A N/A
AU
CSL Ltd
ASX:CSL
28.2
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
NL
argenx SE
XBRU:ARGX
46.9
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Eurobio Scientific SA
PAR:ALERS
Average EV/EBITDA: 14
8.5
10%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 415.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
18%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.2 N/A N/A
AU
CSL Ltd
ASX:CSL
17.4
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.4
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 653.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Eurobio Scientific SA
PAR:ALERS
Average EV/EBIT: 19.3
17.5
34%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 105.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.1
31%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
11%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
13%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 778.9 N/A N/A

See Also

Summary
ALERS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALERS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALERS stock valuation using valuation multiples.
Wall Street Estimates
ALERS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALERS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.